EN PL
PRACA ORYGINALNA
Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis
 
Więcej
Ukryj
 
Data nadesłania: 28-08-2017
 
 
Data akceptacji: 27-09-2017
 
 
Data publikacji online: 28-10-2017
 
 
Data publikacji: 31-10-2017
 
 
Reumatologia 2017;55(5):215-221
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Objective: Prolonged inflammation status due to psoriatic arthritis (PsA) may contribute to the loss of muscle mass, extending from muscle weakness, and increased risk of falls and fractures. The risk of fractures and their complications increases with concomitant osteoporosis.
Material and methods: The study included 95 women aged 50–75 years. The presence of sarcopenia was evaluated in a group of 51 women with PsA, and 44 controls (without inflammatory joint disease). Measurements of muscle mass and lean body mass were made using the method of bioimpedance assessing ALM (Appendicular Lean Mass) index and SMI (Skeletal Muscle Index). The diagnosis of sarcopenia was made in women with low muscle mass and concomitant reduction of the efficiency of the assessed functional test Timed Up and Go (TUG). Bone density measurement was done by densitometry in the femoral neck and lumbar spine. (Ethics statement OIL 625/16/Bioet).
Results: Sarcopenia, using ALM index and SMI, was diagnosed in 13.7% and 43.1% of PsA women, and in healthy women in 9% and 20.4%, respectively. In the group of PsA, sarcopenia was associated with a significant increase in the occurrence of disorders of bone mineralisation (72.7% vs. 41.3% in patients without a decrease in muscle mass). There was no correlation between the loss of muscle mass, bone density, and activity of PsA.
Conclusions: The prevalence of sarcopenia in postmenopausal women suffering from PsA is associated with the occurrence of osteoporosis.
 
REFERENCJE (30)
1.
Giles JT, Ling SM, Ferrucci L, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59: 807-815.
 
2.
Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab 2010; 35: 707-712.
 
3.
Greenlund LJS, Nair KS. Sarcopenia – consequences, mechanisms, and potential therapies. Mech Ageing Dev 2003; 124: 287-299.
 
4.
Binkley N, Buehring B. Beyond FRAX: It’s time to consider “sarco-osteopenia”. J Clin Densitom 2009; 12: 413-416.
 
5.
Pahor M, Manini T, Cesari M. Sarcopenia. Clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging 2009; 13: 724-728.
 
6.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
 
7.
Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis – part I: review of principles and methods. Clin Nutr 2004; 23: 1226-1243.
 
8.
Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU. Arch Osteoporos 2011; 6: 59–155.
 
9.
Taylor W, Gladman D, Helliwell P, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
 
10.
Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.
 
11.
Janssen I, Heymsfield B, Ross R. Low relative skeletal muscle mass (sarcopenia) in older person is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896.
 
12.
Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 2004; 43: 1219-1223.
 
13.
Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-2386.
 
14.
Aguiar R, Sequeira J, Meirinhos T, et al. SARCOSPA – Sarcopenia in spondyloarthritis patients. Acta Reumatol Port 2014; 39: 322-326.
 
15.
Ceyhan Doğan S, Hizmetli S, Hayta E, et al. Sarcopenia in women with rheumatoid arthritis. Eur J Rheumatol 2015, 2: 57-61.
 
16.
Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002; 57: 326-332.
 
17.
Schaap LA, Pluijm SM, Deeg DJ, et al. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006; 119: 5269-5217.
 
18.
Cesari M, Kritchevsky S, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation--results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors study. Am J Clin Nutr 2005; 82: 428-434.
 
19.
Walsmith J, Abad L, Kehayias J, et al. Tumor necrosis factor- production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004; 31: 23-29.
 
20.
Dao HH, Do QT, Sakamoto J. Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1250-1258.
 
21.
Lemmey AB, Wilkinson TJ, Clayton RJ, et al. Tight control of disease activity fails to improve body composition or physical function in rheumatoid arthritis patients. Rheumatology (Oxford) 2016; 55: 1736-1745.
 
22.
Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-1321.
 
23.
Frediani B, Allegri A, Falsetti P, et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001; 28: 138-143.
 
24.
Ogdie A, Harter L, Shin D, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis 2017; 76: 882-885.
 
25.
Borman P, Babaog˘lu S, Gur G, et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008; 27: 443-447.
 
26.
Reid DM, Kennedy NS, Nicoll J, et al. Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis. Clin Rheumatol 1986; 5: 372-378.
 
27.
Nolla JM, Fiter J, Rozadilla A, et al. Bone mineral density in patients with peripheral psoriatic arthritis. Rev Rhum Engl Ed 1999; 66: 657-661.
 
28.
Busquets N, Vaquero CG, Moreno J, et al. Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Rheumatol Clin 2014; 10: 89-93.
 
29.
Dheda K, Cassim B, Patel N, et al. A comparison of bone mineral density in Indians with psoriatic polyarthritis and healthy Indian volunteers. Clin Rheumatol 2004; 23: 89.
 
30.
Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29: 1430-1436.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top